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Abstract
Infantile neuroaxonal dystrophy (INAD) is a progressive, autosomal recessive neurodegenerative disease characterized by
axonal dystrophy, abnormal iron deposition and cerebellar atrophy. This disease was recently mapped to PLA2G6, which
encodes group VI Ca
2+-independent phospholipase A2 (iPLA2 or iPLA2b). Here we show that genetic ablation of PLA2G6 in
mice (iPLA2b
-/-) leads to the development of cerebellar atrophy by the age of 13 months. Atrophied cerebella exhibited
significant loss of Purkinje cells, as well as reactive astrogliosis, the activation of microglial cells, and the pronounced up-
regulation of the pro-inflammatory cytokines tumor necrosis factor-a (TNF-a) and interleukin-1b (IL-1b). Moreover, glial cell
activation and the elevation in TNF-a and IL-1b expression occurred before apparent cerebellar atrophy. Our findings
indicate that the absence of PLA2G6 causes neuroinflammation and Purkinje cell loss and ultimately leads to cerebellar
atrophy. Our study suggests that iPLA2b
-/- mice are a valuable model for cerebellar atrophy in INAD and that early anti-
inflammatory therapy may help slow the progression of cerebellar atrophy in this deadly neurodegenerative disease.
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Introduction
The phospholipase A2 (PLA2) family is a diverse group of
enzymes that catalyzes the hydrolysis of the sn-2 fatty acyl bond of
phospholipids to liberate free fatty acids and lysophospholipids [1].
Among the family members, group VIA PLA2 (iPLA2b) has
unique structural features, including eight N-terminal ankyrin
repeats, caspase-3 cleavage sites, an ATP-binding domain, a serine
lipase consensus sequence (GXSXG), a bipartite nuclear localiza-
tion sequence, and a C-terminal calmodulin-binding domain [1].
The human iPLA2b gene, PLA2G6, maps to chromosome 22q13.1
and encodes several isoforms [2].
Morgan et al. [3] reported that mutations in PLA2G6 underlie
human neurodegenerative disorders, infantile neuroaxonal dys-
trophy (INAD) and neurodegeneration with brain iron accumu-
lation (NBIA). INAD is a neurodegenerative disease with infantile
onset and death as a teenager or in early adulthood. It is
characterized by pathologic axonal swelling and spheroid bodies in
the peripheral and central nervous systems (CNS) [4,5,6].
Mutations in PLA2G6 have recently been identified in many
INAD patients, suggesting that iPLA2b plays an essential role in
the CNS and the development of the disorder.
We used homologous recombination to generate iPLA2b-knockout
mice (iPLA2b
-/-) [7]. These mice developed severe motor dysfunction
associated with the prominent formation of spheroids with tubulove-
sicular membranes remarkably similar to those seen in human INAD
[8,9]. Consistent with the recessive nature of INAD, mutagenesis
analysis demonstrated that the catalytic function of the INAD-
associated mutated PLA2G6 is impaired [10]. Thus, iPLA2b
-/- mouse
is a useful animal model of the pathogenesis of INAD.
The neuroradiological hallmark of INAD is the cerebellar
atrophy. Marked cerebellar atrophy is the most characteristic MRI
feature of INAD patients [11,12,13,14] and observed in almost all
INAD patients with mutations in PLA2G6 [3,4,5,6,15,16,17,18],
suggesting a neuropathologic role of dysfunctional iPLA2b in the
cerebellar atrophy in the INAD patients. Here, we report that
iPLA2b
-/- mice develop severe cerebellar atrophy — characterized
by the loss of Purkinje neurons, the activation of glial cells, and the
elevation of pro-inflammation cytokines — by the age of 13
months. Our findings provide insight into the pathological
mechanisms of cerebellar atrophy in human INAD.
Results
Cerebellar atrophy and Purkinje cell loss in iPLA2b
-/- mice
Cerebellar ataxia is an early symptom of INAD patients with
PLA2G6 mutations [6]. We found that iPLA2b
-/- mice exhibited
ataxia and irregular strides by the age of 13 months, and that these
conditions became more severe with age (Fig 1A). Furthermore,
the cerebella of the iPLA2b
-/- mice were noticeably smaller than
that of the age-matched WT littermates (Fig. 1B) and they weighed
nearly 25 percent less (Fig 1C). These findings indicated that
iPLA2b
-/- mice develop cerebellar atrophy by the age of 13
months that resembles the atrophy seen in humans with INAD.
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-/- mice to
determine the mechanism of cerebellar atrophy. In agreement
with a previous report [8], parasagittal views of nissl-stained mouse
cerebella revealed no apparent anatomical differences between the
iPLA2b
-/- mice and their WT littermates (Figure S1). However,
when we examined the expression of calbindin, a widely used
immunohistochemical marker of Purkinje neurons in the cerebel-
lum [19], we found that, in comparison to the WT controls
(Fig. 2A–B), the Purkinje cell layer and the molecular layer in the
iPLA2b
-/- mice are disrupted (Fig. 2C–F). By stereological
counting of calbindin-positive cells (Figure S2), we found that
iPLA2b
-/- mice have significantly fewer Purkinje cells that the WT
controls (Fig. 2J). Our data suggest that Purkinje cell loss is a
pathologic characteristic of cerebellar atrophy in iPLA2b
-/- mice.
Glial cell activation in the cerebella of iPLA2b
-/- mice
Cerebellar atrophy observed in INAD patients is often
associated with cerebellar gliosis, which is characterized by signal
hyperintensity in the cerebellar cortex on T2-wighted images of
MRI [6]. Since reactive astrogliosis has long been recognized as a
ubiquitous feature of CNS pathologies [20], we determined
whether reactive astrogliosis occurs in the cerebella of the
iPLA2b
-/- mice by examining the expression of glial fibrillary
acidic protein (GFAP), of which up-regulation is the best known
hallmark of reactive astrogliosis in CNS [20]. We found that, with
the exception of the white matter, GFAP levels were very low in
the cerebella of the WT mice (Fig. 3A). However, GFAP levels
were markedly increased in the molecular and granule cell layers
of the cerebella of the iPLA2b
-/- mice (Fig. 3B and 3C). In
consistent with the immunostaining, Western blot analysis (Fig 3D)
and real time quantitative RT-PCR (Fig. 3E) also showed the
significant increase in GFAP expression in the cerebella of the
iPLA2b
-/- mice. This pronounced increase of GFAP in the
molecular and granule cell layers of the cerebella of the iPLA2b
-/-
mice indicate that reactive astrogliosis is a characteristic feature of
cerebellar atrophy in iPLA2b
-/- mice.
Microglial activation plays a central role in reactive astrogliosis
[21]. To determine whether microglial activation also occurs in
the cerebella in the iPLA2b
-/- mice, we examined the expression of
ionized calcium binding adaptor molecule 1 (Iba-1) – a 17-kDa EF
hand protein that is specifically expressed in brain microglia and is
up-regulated during their activation [22]. Iba-1 immunostaining
revealed ramified microglia with small cellular bodies in the
molecular layer and granule cell layer (Fig. 4A, 4C) of the WT
cerebella. In contrast, microglia in the molecular layer and granule
cell layer of the iPLA2b
-/- cerebella displayed features of
activation, including an amoeboid morphology with larger cellular
bodies, thick branches (Fig. 4B, 4D), increased cell numbers
(Fig. 4F), and up-regulated of Iba-1 expression (Fig. 4E, G) [23].
Elevation of proinflammatory cytokines
Activation of microglia often results in the release of pro-
inflammatory cytokines such as TNF-a and IL-1b [24,25]. We
found that although the levels of TNF-a and IL-1b in the serum of
iPLA2b
-/- and WT mice do not differ (Fig. 5A–B), the cerebella of
iPLA2
-/- mice expressed significantly higher levels of these
cytokines (Fig. 5C–D) and their mRNA transcripts (Fig. 5E–F).
Our findings demonstrate that Purkinje cell degeneration is tightly
associated with inflammation in the cerebella of the iPLA2b
-/-
mice.
Glial cell activation and TNF-a and IL-1b production
without apparent cerebellar atrophy
Cerebellar atrophy in the iPLA2b
-/- mice does not become
apparent until the age of 13 months. However, we found that
microglia (Fig. 6B) and astrocytes (Fig. 6D) are activated in the
cerebella of iPLA2b
-/- mice as young as 10 months (Fig. 6A, 6C).
These mice also exhibit significantly increased levels of IL-1b
(Fig. 6E) and TNF-a (Fig. 6F) in their cerebella, which further
increase with age. These elevated cytokine levels can be attributed
to local protein production, as demonstrated by elevated mRNA
levels of IL-1b (Fig. 6G) and TNF-a (Fig. 6H) in the iPLA2b
-/-
mice. Since we observed no significantly difference in the Purkinje
cell layer between the WT and iPLA2b
-/- mice at this age, our
findings suggest that inflammation in the cerebella of iPLA2b
-/-
Figure 1. Ataxia and cerebellar atrophy in the iPLA2b
-/- mouse.
A. Representative footprint patterns in gait stride tests of WT and
iPLA2b
-/- mice. B. Representative cerebellum of iPLA2b
-/- mouse. C.
Cerebella from the iPLA2b
-/- mice (13–18 months) and the age-matched
WT mice (n=15/group) were weighted and statistically analyzed.*
p,0.0001.
doi:10.1371/journal.pone.0026991.g001
Purkinje Cell Loss in iPLA2b
-/- Mice
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-/- mouse. A, B. Representative calbindin staining in the cerebella of the WT mice (18 months). C, D.
Representative calbindin staining in the cerebella of the iPLA2b
-/- mice (13 months), and E, F. (18 months). G. Purkinje cell counting in WT (n=6) and
iPLA2b
-/- mice (n=8) at the age of 13–18 months. p,0.01. Blue color, DAPI staining; pcl, Purkinje cell layer; ml, molecular layer; gcl, granule cell layer;
wm, white matter. White scale bar, 50 mm.
doi:10.1371/journal.pone.0026991.g002
Purkinje Cell Loss in iPLA2b
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and subsequent cerebellar atrophy.
Discussion
In this study, we used a mouse model of INAD [8,9] to
investigate potential mechanisms of cerebellar atrophy — a
hallmark of INAD patients with PLA2G6 mutations
[3,4,5,6,15,16,17,18]. We found that, by the age of 13 months,
iPLA2b
-/- mice exhibited a loss of Purkinje cells and their dendrites
in the molecular layer of the cerebella. Our results indicate that
Purkinje cell loss is a pathologic characteristic of cerebellar atrophy
in iPLA2b
-/- mice.
An important finding in our study is that the cerebellar atrophy
observed in iPLA2b
-/- mice is associated with reactive astrogliosis,
overactivation of microglial cells, and pronounced upregulation of
pro-inflammatory cytokines including IL-1b and TNFa — all
features of neuroinflammation associated with a vast array of CNS
pathologies [26]. Importantly, these features were observed not
only in the cerebella of 13-month-old iPLA2b
-/- mice with
apparent neurological abnormality, but also in younger mice
prior to the onset of overt disease. Our findings suggest that
inflammation may play a pathological role in the development of
cerebellar atrophy in INAD.
Microglia typically exist in a resting state characterized by
ramified morphology (Fig. 3C) monitoring the brain environment
and they are usually the first cells to be activated by pro-
inflammatory stimuli, such as lipopolysaccharide (LPS), or in
response to neuronal damage [24]. In their activated state, they
can serve diverse beneficial functions essential to neuron survival
including cellular maintenance, innate immunity, and regulating
brain development by enforcing the programmed elimination of
neural cells [24]. Indeed, activation of microglia has been reported
to promote the death of developing Purkinje cells during brain
development [27]. However, under certain circumstances, mi-
croglia become overactivated and release excess TNF-a and IL-
1b, which further activate astrocytes and spark a perpetuating
cycle of neuron death [21].
What could cause the overactivation of microglia in the
cerebella of iPLA2b
-/- mice? It is known that the oxidation of
mitochondrial phospholipids, particularly cardiolipin, sets cyto-
chrome c free and release to trigger apoptosis [28]. Mitochon-
Figure 3. Immunofluorescent analyses of GFAP in the cerebella. (A) Representative GFAP/calbindin double-staining in the cerebella of the
WT mice at the age of 13–18 months (n=12). (B, C) GFAP/calbindin double-staining in the cerebella of the iPLA2b
-/- mice at the age of 13–18 months
(n=14). D. Western blot analysis of GFAP in the cerebellum of iPLA2b
-/-. E. qRT-PCR analysis of the cerebellar GFAP mRNA (n=6 each). pcl, Purkinje cell
layer; ml, molecular layer; gcl, granule cell layer; wm, white matter. Scale bar, 50 mm.
doi:10.1371/journal.pone.0026991.g003
Purkinje Cell Loss in iPLA2b
-/- Mice
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inner mitochondrial membranes are particularly susceptible to
ROS attack because they contain a high proportion of
cardiolipin, which is very rich in polyunsaturated fatty acids
[30,31]. Accumulating evidence suggests that iPLA2b-mediated
deacylation of phospholipid is a critical step in maintaining
optimal mitochondrial membrane composition by participating
in cardiolipin remodeling and in repairing of oxidative
modifications caused by mitochondrial ROS production
[32,33,34,35,36,37,38,39]. When iPLA2b is dysfunctional or
missing, Purkinje cells in the cerebellum may be sensitized to
apoptotic induction.
Microglia are phagocytes of myeloid origin that function as the
principal immune effectors in the CNS [40]. They work to
promptly clear apoptotic neuronal cells and prevent the secondary
necrosis and inflammation that can further damage neighboring
neural cells [41]. Previous studies suggest iPLA2b can be
irreversibly activated by caspase-3 activation during apoptosis
[1,42,43] and this activation produces the chemoattractant
lysophosphatidylcholine to recruit professional phagocytes to
engulf the apoptotic cells [43]. Effective clearance of apoptotic
cells is an important physiologic homeostatic mechanism that is
required to prevent secondary necrosis and inflammation [44,45].
In the absence of iPLA2b, apoptotic Purkinje cells may not be
promptly cleared, which can cause overactivation of microglia
[24]. These overactive microglia can produce highly neurotoxic
factors, including superoxide, TNF-a, and IL-1b, which are likely
to perpetuate neuronal death and lead to overt cerebellar atrophy
in iPLA2b
-/- mice.
In summary, Purkinje cell loss is a pathological characteristic of
cerebellar atrophy of the iPLA2b
-/- mice. The loss of functional
iPLA2b in vivo may result in the increase in apoptosis and the
decrease in apoptotic cell clearance, which instigate inflammation.
The presence of reactive astrogliosis, the activation of microglial
Figure 4. Immunofluorescent analyses of Iba-1 in the cerebella. A. Representative Iba-1/calbindin double-staining in the cerebella of the 13–
18 month-old WT mice. B. Representative Iba-1/calbindin double-staining in the cerebella of the iPLA2b
-/- mice at the age of 13–18 months. Confocal
microscopy analysis revealed ramified microglia with small cellular bodies and thin branches in the cerebella of the WT (C) and activated microglia
with amoeboid morphology, larger cellular bodies, and thick branches in the cerebella of the iPLA2b
-/- mice (D). E. Western blot analysis of GFAP in
the cerebellum of iPLA2b
-/-. F. Quantitation of microglial cells in the molecular layer of the mouse cerebellum at the age of 13–18 months. G. qRT-PCR
analysis of the cerebellar Iba-1 mRNA (n=6 each) at the age of 13–18 months. ml, molecular layer; gcl, granule cell layer. Scale bar, 20 mm.
doi:10.1371/journal.pone.0026991.g004
Purkinje Cell Loss in iPLA2b
-/- Mice
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TNF-a and IL-1b in the cerebella of the iPLA2b
-/- mice suggest
that inflammation occurs and inflammation-mediated neurotoxic-
ity may play a role in the pathogenesis of cerebellar atrophy in
INAD. These findings suggest that in vivo microglial imaging by
positron emission tomography (PET) may allow the assessment of
disease progression [24] and that early intervention with anti-
inflammatory therapy may help slow, if not prevent or reverse, the
cerebellar atrophy in INAD.
Materials and Methods
Animals
iPLA2b
-/- mice (C57/BL6 background) and their wild type
(WT) littermates were obtained by mating heterozygote
iPLA2b
+/- mice. Mice were housed in a temperature- and
humidity-controlled facility with a 12-hour light/dark cycle with
standard chow diet and water ad libitum. All animal care and
experimental procedures were approved by the Institutional
Animal Care and Use Committee (IACUC) at the Mount Sinai
School of Medicine.
Gait stride test
Gait stride test was performed as described previously [46].
Briefly, mice in each group were given three training runs each
day for three days, assisted by the home cage on the first day and
unassisted on the next two days. On the fourth day (test), the
mouse’s paws were coated with ink (red ink on the hindpaws and
blue on the forepaws), and paw prints were recorded on two
consecutive runs. Records that displayed the clearest prints and
the most consistent gait for five consecutive strides were chosen for
analysis.
Cerebellar measurements
iPLA2b
-/- mice and their age-matched WT littermates (n=15/
group) were deeply anesthetized by intraperitoneal injection of a
mixture of 100 mg/kg of Ketamine and 20 mg/kg of Xylazine.
Cerebella were carefully collected and weighted.
Cerebellum preparation and immunohistochemistry
Mice were anesthetized by intraperitoneal injection of a mixture
of 100 mg/kg of Ketamine and 20 mg/kg of Xylazine and
Figure 5. Upregulation of IL-1b and TNF-a in the cerebella of the iPLA2b
-/- mice. A. Serum IL-1b levels (WT, n=8; iPLA2b
-/-, n=10). B. Serum
TNF-a levels (WT, n=8; iPLA2b
-/-, n=10). C. Cerebella IL-1b levels (WT, n=6; iPLA2b
-/-, n=6). D. Cerebella TNF-a levels (WT, n=6; iPLA2b
-/-, n=6). E.
Cerebella IL-1b mRNA levels (WT, n=3; iPLA2b
-/-, n=3). F. Cerebella TNF-a mRNA levels (WT, n=3; iPLA2b
-/-, n=3).
doi:10.1371/journal.pone.0026991.g005
Purkinje Cell Loss in iPLA2b
-/- Mice
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26991Figure 6. Glial cell activation and elevation of IL-1b and TNF-a in the cerebella of the iPLA2b
-/- mice before apparent cerebellar
atrophy. A. Representative Iba-1 staining in the cerebella of the WT mice (10-month, n=3) and (B) in the cerebella of the iPLA2b
-/- mice (10-month,
n=6). C. Representative GFAP staining in the cerebella of the WT mice (10-month, n=3) and (D) in the cerebella of the iPLA2b
-/- mice (10-month,
n=6). Scale bar, 100 mm. E. Cerebella IL-1b levels (n = 4 in each group). F. Cerebellar TNF-a levels (n=4 in each group). G. Cerebella IL-1b mRNA
levels (n=3 in each group). H. Cerebella TNF-a mRNA levels (n=3 in each group). * vs. the WT, p,0.01; #vs. the 10-month iPLA2b
-/- mice, p,0.01.
doi:10.1371/journal.pone.0026991.g006
Purkinje Cell Loss in iPLA2b
-/- Mice
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ventricle. The cerebella were removed and further fixed in 4%
paraformaldehyde at 4uC overnight, and then cryopreserved in
30% sucrose.
The cerebellum was cut into 20 mm sections by Leica
Cryomicrotome (Wetzlar, Germany) and standard immunostain-
ing was performed using following primary antibodies: rat anti-
GFAP ( 1:1000; Invitrogen, Carlsbad, CA), rabbit polyclonal anti-
calbindin (1:100; Abcam, Cambridge, MA), and rabbit polyclonal
anti-Iba-1 (1:1000; Biocompare, Richmond, VA). Goat anti-rat/
rabbit IgG with the Alexa FluorH dyes (Alexa FluorH 488,
Invitrogen, Carlsbad, CA) and DyLightH 594 (red) (Vector
Laboratories, Burlingame, CA) were used for the secondary
antibodies. The sections were mounted with VECTASHIELDH
Hard Set
TM Mounting Medium with DAPI (VECTOR Labora-
tories, Burlingame, CA) and coverslipped. All images were
captured by a Zeiss Axioplan 2 microscope and a confocal
microscope (Zeiss LSM 510 META).
Purkinje cell and microglia counts
Purkinje cells in the cerebella were analyzed as described
previously [47]. Briefly, Purkinje cells were quantified by
stereologically counting calbindin positive-cell bodies in 106
images from six entire cerebellar sections of each animal (30 mm
thick and 180 mm apart) were analyzed (control, n=6; iPLA2b
-/-,
n=8). Microglial cells in the molecular layer of the cerebellum
were quantified by counting Iba-1-positive cells.
Western Blot Analysis
Mice were decapitated and cerebella were dissected on ice and
quickly immersed in the buffer (20 mM HEPES, pH 7.4/1 mM
MgCl2/0.25 mM CaCl2/protease inhibitor cocktail/PMSF-pep-
statin/phosphatase inhibitor/DNase 80 U/ml) and homogenized
by Dounce Tissue Homogenizer (Eberbach). Protein was deter-
mined by the BCA method (Pierce), and aliquots of protein per
sample were separated by SDS-PAGE, transferred to nitrocellu-
lose, blotted with corresponding antibodies, and detected by ECL
WESTERN blotting detection system (Amersham Biosciences).
Anti- GFAP antibody (1:1000, Invitrogen), anti-Iba-1 antibody
(1:1000, Biocompare), and anti-actin antibodies (Santa Cruz) were
used for protein detection.
Quantitative Real-time RT-PCR analysis
Total RNA was extracted from the cerebella collected from the
iPLA2b
-/- and age-matched WT mice using an RNeasy Mini Kit.
Primers and probes used in quantitative real-time RT-PCR (qRT-
PCR) were designed by PrimerQuest
SM (IDT SciTools, Coralville,
IA) as follows: GFAP, 59-TCT GAA CCC TCT GAG CAA ATG
CCT-39 and 59-ATT CAC TAC AAG AGC AGC CGT CCA-39,
56-FAM/TG TGG GCA G/Zen/G CTC TGT GTT TGA TTC
A/3IABkFQ; Iba-1, 59-ATG AGC CAA AGC AGG GAT TTG
CAG-39 and 59-AGT TTG GAC GGC AGA TCC TCA TCA-39,
56-FAM/TT TGG ACT G/Zen/C TGA AGG CCC AGC AGG
AA/3IABkFQ; TNF-a,5 9-TCTCATGCACCAC CATCAA-
GACT-39 and 59-ACCACTCTCCCTTTGCAGAACTCA-39,
56-FAM/AATGGGCTT/Zen/TCCGAATTCA CTGGACC-
T/3IABkFQ; IL-1b,5 9-AAGGGCTGCTTCC AAACCTTT-
GAC-39 and 59-ATACTGCCTGCCTGAAGCTCTTGT-39,
56-FAM/ATC CAGCT T/Zen/CAAATCTCG CAGCAGCA/
3IABkFQ; GAPDH, 59-TCAACAGCAAC TCCCACTCTT-
CCA-39 and 59-ACCCTGTTGCTGTAGCCGTATTCA, 56-
FAM/GGCT GGCAT/Zen/TGCTCTCAATGAC AACT/
3IABkFQ. qRT-PCR was performed using an EXPRESS One-
Step SuperScript qRT-PCR Kit from Invitrogen (Carlsbad, CA)
according to the manufacturer’s instructions on 7900HT Real-Time
PCR Systems (Applied Biosystems, Foster City, CA). The mRNA
levels were calculated by comparative CT methods (XTest/
XGAPDH=2
DDC
T) with GAPDH as the endogenous reference
gene.
IL-1b and TNF-a measurements
The levels of cytokines in cerebellum homogenates were
measured as described previously with a modification [48]. Briefly,
mouse blood was collected before sacrificing. The mice were
anesthetized by intraperitoneal injection of a mixture of 100 mg/
kg of Ketamine and 20 mg/kg of Xylazine. Then cerebella were
removed, snap frozen in liquid nitrogen, and stored at 280uC
until use. Cerebellar samples were placed in sterile PBS containing
protease inhibitor cocktail (300 ml solution per 10 mg), homoge-
nized using Tissuemiser (Fisher Scientific, Pittsburgh, PA), and
centrifuged at 11,000 rpm at 4uC for 20 minutes. The superna-
tants or blood were aliquoted and cytokine levels were determined
with mouse TNF-a and IL-1b ELISA Kits (eBioscience, Inc., San
Diago, CA). Cytokine levels were normalized with total proteins
and expressed as ng/mg proteins.
Statistics
Data were expressed as means 6 SEM. Significant differences
were evaluated by unpaired two-tailed Student’s t test by using
PRISM. Significance levels are described in individual figure
legends.
Supporting Information
Figure S1 The nissle staining analysis of mouse cere-
bellum. Nissle staining was performed according to standard
methods. Briefly, the sagittal sections of cerebella from 13-month-
old iPLA2b
-/- mice and the age-matched wild type littermates
(WT) were mounted on slides, dehydrated and rehydrated in
graded ethanols and xylenes, incubated in 1% cresyl violet for 30
sec, decolorized in acetic acid, and then dehydrated and cover-
slipped and analyzed by a a Zeiss Axioplan 2 microscope. The
parasagittal views of the mouse cerebella of the nissl staining
revealed no apparent anatomical differences between the
iPLA2b
-/- and their wild type littermates with the exception of
the less intensive staining in the granule cell layer of cerebella in
iPLA2b
-/- mice. ml, molecular layer; gcl, granule cell layer; DCN,
deep cerebellar nucleus. Scale bar, 100 mm.
(TIF)
Figure S2 The Calbindin staining analysis of mouse
cerebellum. The cerebellum was cut into 20 mm sections by
Leica Cryomicrotome (Wetzlar, Germany) and standard immu-
nostaining was performed by rat anti-GFAP ( 1:1000; Invitrogen,
Carlsbad, CA), rabbit polyclonal anti-calbindin-2 (1:100; abcam,
Cambridge, MA), Goat anti-rat IgG with the Alexa FluorH dyes
(Alexa FluorH 488, Invitrogen, Carlsbad, CA) were used for the
secondary antibodies. Calbindin staining (green) showed the
Purkinje cell lose and degeneration of PC dendrites in iPLA2b
-/-
mice cerebella. ml, molecular layer; gcl, granule cell layer; DCN,
deep cerebellar nucleus. Scale bar, 100 mm.
(TIF)
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